We found that FAM225A was negatively correlated with the severity of clinical symptoms, suggesting that FAM225A may become a new biomarker for diagnosis and curative effect inspection, and a new target for treatment of triple-SN MG. This evidence concerns the gene FAM225A and myasthenia gravis.